目的:本研究旨在分析健脾生血片治疗肾性贫血的临床疗效。
方法:纳入2020年12月至2022年12月的200例肾性贫血患者,随机分为两组。对照组患者给予多糖铁复合物治疗,实验组给予健脾生血片。连续治疗8周后,比较了两组患者贫血的治疗结果.
结果:治疗后,红细胞(RBC)计数,血细胞比容(HCT),网织红细胞百分比(RET),铁蛋白(SF),血清铁(SI),转铁蛋白饱和度(TSAT),血清白蛋白(ALB)均升高(P<0.01),实验组临床症状评分和总铁结合力下降(P<0.01)。此外,RBC的改进,HCT,RET,SF,SI,TAST,ALB,和临床症状(疲劳,厌食症,暗沉的皮肤肤色,手脚麻木)明显大于对照组(P<0.05)。试验组治疗肾性贫血的总有效率明显高于对照组(P<0.01)。
结论:健脾生血片治疗肾性贫血疗效确切,导致肾性贫血患者的实验室检查结果和临床症状明显改善。
OBJECTIVE: This study aimed to analyze the clinical efficacy of the Jianpi Shengxue tablet for treating renal anemia.
METHODS: A total of 200 patients with renal anemia from December 2020 to December 2022 were enrolled and randomly divided into two groups. Patients in the control group were treated with polysaccharide-iron complex, and those in the experimental group were administered Jianpi Shengxue tablet. After 8 weeks of continuous treatment, the therapeutic outcomes regarding anemia were compared between the two groups.
RESULTS: After treatment, the red blood cell (RBC) count,
hematocrit (HCT), reticulocyte percentage (RET), ferritin (SF), serum iron (SI), transferrin saturation (TSAT), and serum albumin (ALB) all increased (P<0.01), and the clinical symptom score and total iron binding capacity decreased (P<0.01) in the experimental group. Moreover, the improvements in RBC, HCT, RET, SF, SI, TAST, ALB, and clinical symptoms (fatigue, anorexia, dull skin complexion, numbness of hands and feet) in the experimental group were significantly greater than those in the control group (P<0.05). The total effective rate for treating renal anemia was significantly higher in the experimental group than in the control group (P<0.01).
CONCLUSIONS: The Jianpi Shengxue tablet demonstrates efficacy in treating renal anemia, leading to significant improvements in the laboratory examination results and clinical symptoms of patients with renal anemia.